0001104659-20-051570.txt : 20200528 0001104659-20-051570.hdr.sgml : 20200528 20200427154528 ACCESSION NUMBER: 0001104659-20-051570 CONFORMED SUBMISSION TYPE: CORRESP PUBLIC DOCUMENT COUNT: 2 FILED AS OF DATE: 20200427 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Protalix BioTherapeutics, Inc. CENTRAL INDEX KEY: 0001006281 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 650643773 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: CORRESP BUSINESS ADDRESS: STREET 1: 2 SNUNIT ST STREET 2: SCIENCE PARK, POB 455 CITY: CARMIEL STATE: L3 ZIP: 2161401 BUSINESS PHONE: 972-4-988-9488 MAIL ADDRESS: STREET 1: 2 SNUNIT ST STREET 2: SCIENCE PARK, POB 455 CITY: CARMIEL STATE: L3 ZIP: 2161401 FORMER COMPANY: FORMER CONFORMED NAME: ORTHODONTIX INC DATE OF NAME CHANGE: 19980422 FORMER COMPANY: FORMER CONFORMED NAME: EMBASSY ACQUISITION CORP DATE OF NAME CHANGE: 19960124 CORRESP 1 filename1.htm

April 27, 2020

VIA EDGAR

Jeffrey Gabor

Office of Life Sciences

U.S. Securities and Exchange Commission

Division of Corporation Finance

Mail Stop 4720

100 F Street, N.E.

Washington, D.C. 20549

Re:

Protalix BioTherapeutics, Inc.
Registration Statement on Form S-3

Filed April 17, 2020
File No. 333-237736

Dear Mr. McCann:

We refer to the registration statement on Form S-3 (File No. 333-237736) (the “Registration Statement”) of Protalix BioTherapeutics, Inc., a Delaware corporation (the “Company”). In accordance with Rule 461 under the Securities Act of 1933, as amended, the Company hereby respectfully requests the acceleration of the effectiveness of the Registration Statement so that it may become effective at 4:30 p.m. (Eastern time) on April 29, 2020 or as soon as practicable thereafter.

We thank you in advance for your time and attention to the Registration Statement. Should you wish to discuss the enclosed materials at any time, please do not hesitate to contact me at +972 (4) 902-8100 or Eyal.Rubin@protalix.com, or the Company’s counsel, Anna T. Pinedo of Mayer Brown LLP at +1 (212) 506-2275 or apinedo@mayerbrown.com.

Sincerely,

/s/ Eyal Rubin

Eyal Rubin
Sr. Vice President and Chief Financial Officer
Protalix BioTherapeutics, Inc.

cc:	Dror Bashan
	Protalix BioTherapeutics, Inc.

	Anna T. Pinedo
	Mayer Brown LLP

2 Snunit Street, Science Park P.O.B. 455, Carmiel 20100, Israel

Tel: 972-4-988-9488 | Fax: 972-4-988-9489 | Web: www.protalix.com

GRAPHIC 2 image_002.jpg GRAPHIC begin 644 image_002.jpg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